Study guide
14.3 Neoplasia: Benign vs Malignant Features, Carcinogenesis, Oncogenes, and Tumor Suppressors
NPLEX Part I — Biomedical Sciences Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Pacing, and GEA Strategy
1.1 Overview of NPLEX Part I & NABNE Exam Structure 1.2 Deconstructing Biomedical Clinical Vignettes 1.3 General Exam Areas (GEAs) & Passing Standards
2 Chapter 2: Gross Anatomy & Musculoskeletal System
2.1 Musculoskeletal Anatomy of Upper and Lower Extremities 2.2 Structural Anatomy of Head, Neck, Thorax, and Abdomen 2.3 Pelvic Architecture, Perineal Anatomy, and Articular Structures
3 Chapter 3: Histology & Microscopic Anatomy
3.1 Histology of Epithelial, Connective, and Muscular Tissues 3.2 Microscopic Structure of Gastrointestinal, Renal, and Endocrine Organs 3.3 Microscopic Anatomy of Integument, Lymphoid Tissues, and Respiratory Epithelium
4 Chapter 4: Neuroanatomy & Special Senses
4.1 Cranial Nerves, Nuclei, and Peripheral Distribution 4.2 Spinal Cord Tracts, Brainstem Circuits, and Motor/Sensory Pathways 4.3 Cerebral Cortex, Basal Ganglia, Limbic System, and Autonomic Nervous System 4.4 Neuroanatomy of Vision, Audition, Vestibular Function, and Olfaction/Gustation
5 Chapter 5: Embryology & Developmental Anatomy
5.1 Gametogenesis, Fertilization, Blastulation, and Germ Layer Derivatives 5.2 Organogenesis: Cardiovascular and Respiratory System Development 5.3 Gastrointestinal, Urogenital, and Craniofacial Embryology
6 Chapter 6: Cellular & General Physiology
6.1 Membrane Transport Mechanics, Resting Potentials, and Ion Channels 6.2 Action Potential Propagation and Synaptic Transmission 6.3 Excitation-Contraction Coupling in Skeletal, Cardiac, and Smooth Muscle
7 Chapter 7: Cardiovascular & Respiratory Physiology
7.1 Cardiac Electrophysiology, ECG, and Mechanical Cardiac Cycle 7.2 Hemodynamics, Peripheral Resistance, and Blood Pressure Control 7.3 Pulmonary Mechanics, Lung Volumes, and Gas Exchange Dynamics 7.4 Transport of Oxygen/CO2 and Neural/Chemical Control of Breathing
8 Chapter 8: Renal, Fluid, & Acid-Base Physiology
8.1 Glomerular Filtration Rate and Tubular Reabsorption/Secretion Mechanics 8.2 Countercurrent Multiplication, Osmoregulation, and Urine Concentration 8.3 Body Fluid Compartments, Sodium/Water Homeostasis, and Potassium Dynamics 8.4 Renal & Respiratory Acid-Base Regulation and Compensation Mechanisms
9 Chapter 9: Gastrointestinal, Endocrine, & Reproductive Physiology
9.1 GI Motility, Secretory Functions, Digestion, and Nutrient Absorption 9.2 Hypothalamic-Pituitary Axes, Adrenal Gland, and Thyroid Physiology 9.3 Endocrine Pancreas, Glucose Regulation, Calcium/Phosphate Homeostasis 9.4 Male and Female Reproductive Endocrinology and Menstrual Cycle Regulation
10 Chapter 10: Enzymology, Bioenergetics, & Carbohydrate/Lipid Metabolism
10.1 Enzyme Kinetics, Catalytic Mechanisms, and Vitamin Cofactors 10.2 Glycolysis, Pyruvate Dehydrogenase, TCA Cycle, and Oxidative Phosphorylation 10.3 Glycogen Metabolism, Gluconeogenesis, and Pentose Phosphate Pathway 10.4 Fatty Acid Synthesis, Beta-Oxidation, Ketogenesis, and Lipoprotein Transport
11 Chapter 11: Amino Acid/Nucleotide Metabolism & Clinical Genetics
11.1 Amino Acid Degradation, Transamination, and Urea Cycle Disorders 11.2 Purine and Pyrimidine Synthesis, Salvage, and Gout Pathophysiology 11.3 Mendelian Inheritance, Chromosomal Abnormalities, and Molecular Genetics
12 Chapter 12: Immunology & Immunopathology
12.1 Innate Immune Barriers, Phagocytosis, Cellular Pattern Recognition, and Complement System 12.2 Adaptive Immunity: T-Cell & B-Cell Activation, MHC Restriction, and Antibodies 12.3 Types I-IV Hypersensitivity Reactions and Mechanisms of Autoimmunity 12.4 Immunodeficiency Syndromes, Tumor/Transplant Immunology, and Vaccine Types
13 Chapter 13: Medical Microbiology
13.1 Medical Bacteriology: Gram-Positive, Gram-Negative, and Atypical Bacteria 13.2 Medical Virology: DNA, RNA, Retroviruses, and Viral Pathogenesis 13.3 Medical Mycology: Cutaneous, Systemic, and Opportunistic Fungal Infections 13.4 Medical Parasitology: Protozoan and Helminthic Pathogens
14 Chapter 14: General Pathology & Neoplasia
14.1 Cellular Adaptation, Reversible/Irreversible Injury, Necrosis, and Apoptosis 14.2 Acute and Chronic Inflammation, Chemical Mediators, and Tissue Healing 14.3 Neoplasia: Benign vs Malignant Features, Carcinogenesis, Oncogenes, and Tumor Suppressors
15 Chapter 15: Systems Pathology & Disease Mechanisms
15.1 Pathophysiology of Atherosclerosis, Heart Failure, COPD, and Pneumonias 15.2 Glomerulonephritis, Inflammatory Bowel Disease, and Hepatorenal Disease Pathophysiology 15.3 Endocrine Disorders, Neurodegenerative Pathology, and Epidemiological Principles 15.4 Hematopoietic System Pathology: Anemias, Coagulopathies, and Hematologic Neoplasms 15.5 Immunological System Pathology: Autoimmune, Amyloid, and Systemic Immune-Mediated Disease 15.6 Integumentary System Pathology: Inflammatory Dermatoses, Blistering Disorders, and Skin Neoplasms 15.7 Musculoskeletal System Pathology: Metabolic Bone Disease, Arthropathies, and Bone Neoplasms 15.8 Reproductive System Pathology: Endocrine, Inflammatory, and Neoplastic Disorders of the Reproductive Tract
14.3 Neoplasia: Benign vs Malignant Features, Carcinogenesis, Oncogenes, and Tumor Suppressors
Key Takeaways Explain This Topic AI
Benign tumors are well-differentiated, slow-growing, encapsulated, and non-metastatic; malignant tumors are anaplastic, invasive, rapid-growing, and metastatic.
Anaplasia hallmarks include pleomorphism, nuclear hyperchromasia, high N:C ratio, prominent nucleoli, and atypical mitotic figures.
Proto-oncogenes require single-allele gain-of-function mutations (e.g., KRAS, BRAF, HER2, c-MYC, BCL-2, BCR-ABL), whereas tumor suppressors follow Knudson's two-hit loss-of-function rule (e.g., TP53, RB1, APC, BRCA1/2, VHL).
p53 arrests the cell cycle at G1/S via p21 or activates Bax apoptosis, while Rb sequesters E2F until phosphorylated by CDK4/6.
Paraneoplastic syndromes reflect remote tumor effects, such as SIADH/ACTH/Lambert-Eaton in small cell lung cancer, and PTHrP hypercalcemia in squamous cell lung cancer.
Last updated: July 2026
14.3 Neoplasia: Benign vs Malignant Features, Carcinogenesis, Oncogenes, and Tumor Suppressors
Neoplasia ("new growth") refers to an abnormal, uncontrolled, uncoordinated proliferation of cells that persists even after the cessation of the initiating stimulus. Neoplastic transformation results from accumulated genetic mutations that alter proto-oncogenes, tumor suppressor genes, and DNA repair pathways. Master knowledge of tumor classification, molecular oncogenesis, and paraneoplastic syndromes is vital for NPLEX Part I success.
Benign vs. Malignant Neoplasms: Classification and Features
Neoplasms are divided into benign and malignant categories based on their histological differentiation, growth kinetics, local invasiveness, and metastatic capability.
Feature Benign Neoplasm Malignant Neoplasm
Differentiation Well-differentiated; resembles tissue of origin. Poorly differentiated to anaplastic (undifferentiated).
Rate of Growth Usually slow, progressive; may stabilize or regress. Rapid, erratic; frequent normal and atypical mitotic figures .
Local Invasion Non-invasive; circumscribed, often encapsulated . Infiltrative; lacks capsule, destroys surrounding parenchyma.
Metastasis Absent (never metastasizes). Present (hallmark of malignancy; lymph node or hematogenous).
Neoplastic Nomenclature Rules
Tumors are named according to their parenchymal cell origin and histological pattern:
Epithelial Origin:
Benign: Adenoma (glandular pattern), Papilloma (finger-like epithelial projections).
Malignant: Adenocarcinoma (malignant glandular tissue), Squamous Cell Carcinoma (malignant squamous epithelium).
Mesenchymal Origin (Connective Tissue, Muscle, Bone):
Benign: Fibroma (fibrous tissue), Leiomyoma (smooth muscle), Lipoma (adipose tissue).
Malignant: Fibrosarcoma (malignant fibrous tissue), Leiomyosarcoma (malignant smooth muscle), Osteosarcoma (malignant bone).
Cytological Features of Anaplasia
Anaplasia ("to form backward") is the hallmark of high-grade malignancy. Histological characteristics include:
Pleomorphism: Extreme variation in cellular size and shape.
Hyperchromatic Nuclei: Darkly stained nuclei with coarsely clumped chromatin.
High N:C Ratio: Increased nuclear-to-cytoplasmic ratio approaching 1:1 (normal is 1:4 or 1:6).
Prominent Nucleoli: Abnormally large or multiple nucleoli.
Atypical Mitoses: Abnormal mitotic figures (e.g., tripolar or quadripolar spindles).
Molecular Hallmarks of Cancer
Hanahan and Weinberg outlined the essential cellular adaptations required for malignant transformation: Sustained Proliferative Signaling
- \u2502
- Evading Growth Suppressors (Rb/p53)
- \u2502
- Resisting Cell Death (Apoptosis)
- \u2502
- Limitless Replicative Potential (Telomerase)
- \u2502
- Inducing Angiogenesis (VEGF)
- \u2502
- Activating Invasion & Metastasis (Loss of E-Cadherin)
- \u2502
- Reprogramming Energy Metabolism (Warburg Effect)
- \u2502
- Evading Immune Destruction (PD-L1)
Tissue Invasion and Metastasis: Occurs in a defined sequence:
Downregulation of E-cadherin , loosening intercellular attachments.
Attachment to basement membrane laminin.
Degradation of basement membrane matrix via Type IV collagenases (MMP-2 and MMP-9) .
Migration through vascular walls and survival in circulation.
The Warburg Effect: Cancer cells preferentially utilize aerobic glycolysis (converting glucose to lactate even in the presence of abundant oxygen) to generate metabolic intermediates required for rapid biomass assembly.
Oncogenes: Gain-of-Function Driver Mutations
Proto-oncogenes are normal physiological genes involved in cell growth and division. When mutated into oncogenes , a single allele gain-of-function mutation (dominant effect) drives persistent, unregulated cellular proliferation.
Oncogene Molecular Function Associated Malignancies
KRAS GTPase signal transduction protein downstream of RTKs. Pancreatic adenocarcinoma, Colorectal cancer, Non-small cell lung cancer.
BRAF Serine/threonine kinase (frequent V600E point mutation ). Cutaneous Melanoma, Papillary Thyroid Carcinoma, Colorectal cancer.
HER2/neu (ERBB2) Receptor tyrosine kinase amplification. Aggressive subtype of Breast Carcinoma.
EGFR Epidermal growth factor receptor tyrosine kinase mutation. Lung Adenocarcinoma (especially in non-smokers).
c-MYC Transcription factor; t(8;14) translocation to Ig heavy chain locus. Burkitt Lymphoma (starry-sky histology).
N-MYC Nuclear transcription factor gene amplification. Neuroblastoma (adrenal tumor in pediatric patients).
BCL-2 Anti-apoptotic protein; t(14;18) translocation to Ig heavy chain. Follicular Lymphoma (prevents apoptosis of B cells in germinal centers).
BCR-ABL Hybrid tyrosine kinase resulting from t(9;22) Philadelphia chromosome . Chronic Myelogenous Leukemia (CML) .
Tumor Suppressor Genes: Loss-of-Function Mutations
Tumor suppressor genes regulate cell cycle checkpoints, promote apoptosis, or repair damaged DNA. Tumor suppressors obey Knudson’s Two-Hit Hypothesis : both alleles must be inactivated (loss-of-function, recessive effect) to promote oncogenesis. Normal Alleles (TSG+/TSG+) \u2500\u2500\u2500> First Hit (Germline or Somatic Mutation)
- \u2502
- \u25bc
- Heterozygous (TSG+/TSG-)
- \u2502
- Second Hit (Somatic Deletion/Mutation)
- \u2502
- \u25bc
- Nullizygous Loss of Function
- \u2502
- \u25bc
- Uncontrolled Proliferation
- Major Tumor Suppressors and Syndromes
TP53 (p53 — "Guardian of the Genome"):
Mechanism: DNA damage activates p53, which induces p21 (CDK inhibitor) to arrest the cell cycle at the G1/S checkpoint for DNA repair. If repair fails, p53 upregulates Bax to trigger apoptosis.
Syndrome: Li-Fraumeni Syndrome (inherited germline mutation causing multiple early-onset carcinomas and sarcomas).
RB1 (Retinoblastoma Gene):
Mechanism: Hypophosphorylated Rb protein binds and sequesters the E2F transcription factor , blocking G1 -> S progression. Phosphorylation of Rb by cyclin D/CDK4/6 releases E2F, advancing the cell cycle.
Syndrome: Familial Retinoblastoma (bilateral ocular tumors) and Osteosarcoma.
APC (Adenomatous Polyposis Coli):
Mechanism: Degradation complex protein that breaks down beta-catenin, inhibiting Wnt signaling.
Syndrome: Familial Adenomatous Polyposis (FAP) (thousands of colonic polyps progressing to colon adenocarcinoma).
BRCA1 and BRCA2:
Mechanism: Proteins involved in homologous recombination repair of DNA double-strand breaks.
Syndrome: Hereditary Breast and Ovarian Cancer syndrome (BRCA1 carries high risk for serous ovarian carcinoma).
VHL (Von Hippel-Lindau):
Mechanism: Ubiquitin ligase component that targets HIF-1-alpha (hypoxia-inducible factor) for degradation. Loss leads to constitutive HIF-1-alpha activation and VEGF expression.
Syndrome: Clear cell Renal Cell Carcinoma, cerebellar hemangioblastomas, and pheochromocytomas.
WT1: Wilms Tumor (pediatric renal neoplasm).
NF1 & NF2: Neurofibromatosis Type 1 (neurofibromin protein, Ras-GAP activator) and Neurofibromatosis Type 2 (Merlin protein, bilateral acoustic neuromas).
Paraneoplastic Syndromes
Paraneoplastic syndromes are systemic signs or symptoms caused by tumor secretion of functional hormones or peptides, or by cross-reactive antibodies, rather than local tumor invasion or metastasis.
Paraneoplastic Condition Secreted Substance / Mechanism Primary Underlying Malignancy
SIADH Ectopic Antidiuretic Hormone (ADH) secretion causing hyponatremia. Small Cell Lung Cancer (SCLC) .
Cushing Syndrome Ectopic ACTH secretion causing hypercortisolemia. Small Cell Lung Cancer (SCLC) .
Hypercalcemia of Malignancy Ectopic Parathyroid Hormone-related Peptide (PTHrP) production. Squamous Cell Lung Carcinoma , Renal Cell Carcinoma.
Lambert-Eaton Myasthenic Syndrome Autoantibodies against presynaptic voltage-gated Ca2+ channels . Small Cell Lung Cancer (SCLC) .
Acanthosis Nigricans / Leser-Trélat Growth factor secretion (e.g., TGF-alpha) causing dark velvety skin / seborrheic keratoses. Gastric Adenocarcinoma .